BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aphton Corporation (APHT) Announces Closing Of Igeneon Acquisition


10/19/2005 5:13:07 PM

PHILADELPHIA--(BUSINESS WIRE)--March 24, 2005--Aphton Corporation (NASDAQ:APHT), a biopharmaceutical company focused on the development of immunotherapies for the treatment of cancer, announced the formal completion of its acquisition of Igeneon AG, a biopharmaceutical company based in Vienna, Austria. Pursuant to the agreement, Igeneon equity holders will receive an aggregate of 21.5 million shares of Aphton common stock in exchange for 100% of the equity of Igeneon. Igeneon AG will become a wholly owned subsidiary of Aphton Corporation. "This acquisition is a key component of Aphton's strategy to create an innovative global oncology company," said Patrick Mooney, M.D., Chief Executive Officer of Aphton. "We believe the addition of Igeneon's people, products and research capabilities will provide us with the depth and experience to expand our current capacity and are a complement to Aphton's people and programs."

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES